Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

2,719

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

MF59-eH1N1_f

8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant

Trial Locations (21)

13760

Regional Clinical Research, Endwell

14000

Instituto Nacional de Ciencias, Tlalpan

14609

Rochester Clinical Research, Inc, Rochester

15025

Primary Physicians Research Inc. (adult), Jefferson Hills

16506

West Ridge Family Practice (adult), Erie

22015

PI-Coor Clinical Research, Burke

22030

PI Coor Clinical Research, Fairfax

23219

Virginia Commonwealth University, Richmond

27103

Carolina Medical Trials, Winston-Salem

27518

Triangle Medical Research Associates, Cary

27609

Triangle Medical Research Associates, Raleigh

33143

Miami Research Associates, Miami

45005

Prestige Clinical Research, Franklin

66219

Johnson County Clin-Trials, Lenexa

68134

Meridien Clinical Research, Omaha

73103

IPS Research, Oklahoma City

75234

Research Across America, Dallas

77055

West Houston Clinical Research Service, Houston

84109

J.Lewis Research, Inc./Foothill Family Clinic, Salt Lake City

84121

J. Lewis Research, Inc./Foothill Family Clinic South, Salt Lake City

02886

Omega Clinical Research, Warwick

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY